*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI hosted a Twitter Chat, moderated by STAT’s Sharon Begley, discussing takeaways from the ASCO19 conference last week.
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers, and cellular immunotherapy.